<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480802</url>
  </required_header>
  <id_info>
    <org_study_id>V114-018</org_study_id>
    <secondary_id>V114-018</secondary_id>
    <secondary_id>2017-001909-32</secondary_id>
    <nct_id>NCT03480802</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to 1) describe the safety, tolerability, and immunogenicity of V114
      and Prevnar 13™ in pneumococcal vaccine-naïve adults infected with HIV and to 2) describe the
      safety, tolerability, and immunogenicity of PNEUMOVAX™23 when administered 8 weeks after
      receipt of either V114 or Prevnar 13™.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 6, 2018</start_date>
  <completion_date type="Actual">January 17, 2020</completion_date>
  <primary_completion_date type="Actual">January 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after Vaccination 1</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness, swelling, and pain/tenderness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after Vaccination 1</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain, joint pain, headache, and tiredness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with a Vaccine-related Serious Adverse Event</measure>
    <time_frame>Up to Month 6</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine will be determined by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)</measure>
    <time_frame>Day 30</time_frame>
    <description>OPA for the serotypes contained in V114 will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific Immunoglobulin G (IgG)</measure>
    <time_frame>Day 30</time_frame>
    <description>IgG for the serotypes contained in V114 will be determined using an electrochemiluminescence assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Injection-site Adverse Event</measure>
    <time_frame>Up to Day 5 after Vaccination 2</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited injection-site AEs will be redness, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Solicited Systemic Adverse Event</measure>
    <time_frame>Up to Day 14 after Vaccination 2</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Solicited systemic AEs will be muscle pain, joint pain, headache, and tiredness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Serotype-specific OPA</measure>
    <time_frame>Week 12</time_frame>
    <description>OPA for the serotypes contained in V114 will be determined using a Multiplex Opsonophagocytic Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentration of Serotype-specific IgG</measure>
    <time_frame>Week 12</time_frame>
    <description>IgG for the serotypes contained in V114 will be determined using an electrochemiluminescence assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">302</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>V114</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single 0.5 mL IM injection of Prevnar 13™ on Day 1 (Vaccination 1) and a single 0.5 mL IM injection of PNEUMOVAX™23 at Week 8 (Vaccination 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V114</intervention_name>
    <description>15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose</description>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar 13™</intervention_name>
    <description>13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PNEUMOVAX™23</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine with serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F (25 mcg each) in each 0.5 mL dose</description>
    <arm_group_label>Prevnar 13™</arm_group_label>
    <arm_group_label>V114</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female infected with human immunodeficiency virus (HIV) and Cluster of
             Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid
             (RNA) &lt;50,000 copies/mL

          -  Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before
             enrollment with no intention of changing therapy for 3 months after randomization

          -  Female participant: not pregnant, not breastfeeding and 1) not of childbearing
             potential, or 2) of childbearing potential and agrees to practice contraception
             through 6 weeks after administration of study vaccine.

        Exclusion Criteria:

          -  History of opportunistic infections within 12 months before the first study
             vaccination

          -  History of non-infectious acquired immune deficiency syndrome-related illness such as
             Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy

          -  History of invasive pneumococcal disease

          -  Known hypersensitivity to any vaccine component

          -  Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or
             history of autoimmune disease

          -  Coagulation disorder contraindicating intramuscular vaccination

          -  History of malignancy ≤5 years before enrollment, except for adequately treated basal
             cell or squamous cell skin cancer or in situ cervical cancer

          -  Female participant: positive urine or serum pregnancy test

          -  Prior administration of any pneumococcal vaccine

          -  Received systemic corticosteroids for ≥14 consecutive days and have not completed
             within 30 days of enrollment

          -  Received immunosuppressive therapy

          -  Received a blood transfusion or blood products within 6 months of enrollment

          -  Participated in another clinical study of an investigational product within 2 months
             of enrollment

          -  Current user of recreational or illicit drugs or history of drug or alcohol abuse or
             dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bliss Healthcare Services ( Site 0010)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A. ( Site 0011)</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Hope Foundation, Inc. ( Site 0009)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc. ( Site 0002)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Gabriel Montpied ( Site 0084)</name>
      <address>
        <city>Clemont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis ( Site 0094)</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin du Paris ( Site 0089)</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Libre ( Site 0043)</name>
      <address>
        <city>Lima</city>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigaciones Medicas en Salud - INMENSA ( Site 0041)</name>
      <address>
        <city>Lima</city>
        <zip>15046</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Hospital ( Site 0122)</name>
      <address>
        <city>Johannesburg</city>
        <state>Soweto</state>
        <zip>1862</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Part Yoluntu Centre ( Site 0123)</name>
      <address>
        <city>Paarl</city>
        <state>Western Cape</state>
        <zip>7626</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hosp (Prev&amp;Social Med). ( Site 0183)</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute for Health. ( Site 0182)</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Peru</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 22, 2018</study_first_submitted>
  <study_first_submitted_qc>March 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjugate pneumococcal vaccine, 15-valent, 22F, 33F</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

